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Abstract
Purpose Statins are the first-choice pharmacological treat-
ment for patients with hypercholesterolemia and at risk for
cardiovascular disease; however, a minority of patients expe-
rience statin-associated symptoms (SAS) and are considered
to have reduced statin tolerance. The objective of this study
was to establish how patients with SAS are identified and
managed in clinical practice in Austria, Belgium, Colombia,
Croatia, the Czech Republic, Denmark, Portugal, Switzerland,
Russia, Saudi Arabia, Turkey, and the United Arab Emirates.
Methods A cross-sectional survey was conducted (2015–
2016) among clinicians (n = 60 per country; Croatia: n = 30)
who are specialized/experienced in the treatment of hypercho-
lesterolemia. Participants were asked about their experience of
patients presenting with potential SAS and how such patients
were identified and treated.
Results Muscle-related symptoms were the most common
presentation of potential SAS (average: 51%; range across
countries [RAC] 17–74%); other signs/symptoms included
persistent elevation in transaminases. To establish whether
symptoms are due to statins, clinicians required rechallenge
after discontinuation of statin treatment (average: 77%; RAC
40–90%); other requirements included trying at least one al-
ternative statin. Clinicians reported that half of high-risk pa-
tients with confirmed SAS receive a lower-dose statin (aver-
age: 53%; RAC 43–72%), and that most receive another non-
statin lipid-lowering therapy with or without a concomitant
statin (average: 65%; RAC 52–83%).
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Conclusions The specialists and GPs surveyed use stringent
criteria to establish causality between statin use and signs or
symptoms, and persevere with statin treatment where
possible.
Keywords Hypercholesterolemia . Statin-associatedmuscle
symptoms . Statin-associated symptoms . Reduced statin
tolerance . Clinical practice
Background
Statins are the first-choice pharmacological treatment to re-
duce circulating levels of low-density lipoprotein cholesterol
(LDL-C), an important and modifiable risk factor for cardio-
vascular disease [1, 2]. The incidence of reported adverse
events attributed to statins is low in clinical trials [3, 4]; how-
ever, in observational studies, approximately 10% of patients
experience side effects (statin-associated symptoms [SAS])
[5–8]. The most commonly reported SAS are statin-
associated muscle symptoms (SAMS), such as muscle dis-
comfort or weakness [9–11]; other less common presentations
that may be attributed to SAS include hepatic, gastrointestinal,
or central nervous system (CNS) effects [12].
Patients with SAS may require a decrease in dose or com-
plete discontinuation of statin therapy [12]. This limits effec-
tive treatment, putting patients at increased risk of cardiovas-
cular morbidity and mortality [13, 14]. National and interna-
tional clinical guidelines have been developed in recent years
to help clinicians evaluate and manage patients with SAS in
clinical practice [2, 9–12, 15, 16]. Such guidelines provide
pragmatic definitions of SAMS, and SAS in general, which
include new approaches using the terminology Bgoal-
inhibiting statin intolerance^ that emphasize the effect of such
symptoms on the ability to achieve lipid-lowering goals
through adequate therapy or optimally reduce cardiovascular
risk [9].
Even with the publication of guidelines, it remains unclear
how clinicians manage patients presenting with SAS in clini-
cal practice. In 2014, we conducted a survey of clinicians in 13
countries to establish how patients with SAS are identified and
managed in clinical practice [17]. In 2015–2016, this work
was extended to include a further 12 countries, to gain a
broader understanding of treatment practice across additional
countries and regions.
Material and Methods
This cross-sectional survey was conducted among clinicians
who specialize in the treatment of patients with hypercholes-
terolemia in Austria, Belgium, Colombia, Croatia, the
Czech Republic, Denmark, Portugal, Switzerland, Russia,
Saudi Arabia, Turkey, and the United Arab Emirates (UAE).
The survey was conducted between December 2015 and
August 2016.
Questionnaire Development and Administration
The questionnaire was based on the one used in 2014 for the
initial 13 countries [17]. The original questionnaire was
reviewed by a clinical advisor before face validity was
assessed through interviews with clinicians in seven of the
original scope countries to ensure the questions were relevant,
comprehensible, unambiguous, and asked only a single ques-
tion. Analysis of the 2014 survey data served as further vali-
dation of the questionnaire.Minor modifications were made to
the original questionnaire used in 2014 following discussions
with clinicians, to account for the publication of clinical guide-
lines on SAS since the original survey and to improve the
clarity of some questions. The participating clinicians were
asked about their clinical experience of patients presenting
with potential SAS, how patients with SAS were confirmed,
and what treatment was subsequently started in these patients.
No further validation was undertaken. Clinicians were asked
to answer the questionnaire based on recollection of their ex-
perience in routine clinical practice. A summary of the ques-
tionnaire is available in the Supplementary Materials.
The survey was provided to clinicians in their local lan-
guage using a web-based platform in all countries except
Saudi Arabia and the UAE, where clinicians completed the
survey at a face-to-face appointment with a researcher (clini-
cian responses to survey questions were entered by the re-
searcher into an offline copy of the survey). A pilot phase
was conducted in all countries except Croatia; for this phase,
two clinicians in each country completed the survey and pro-
vided feedback in a telephone interview. This feedback was
used to confirm the face validity of the questionnaire in the
local language, and to identify country-specific items to incor-
porate into the questionnaire (e.g., national guidelines).
Recruitment and data collection were performed by agen-
cies specializing in healthcare fieldwork; clinicians were re-
cruited by invitations sent to a panel of clinicians who had
previously agreed to participate in healthcare research sur-
veys. All participants were remunerated for their time at the
fair market value rate prevalent in their country.
Participants
Eligible clinicians had to be specialists (mainly cardiologists,
with a small number of endocrinologists also recruited in
Russia, Saudi Arabia, and the UAE to reflect local practices)
or general/family physicians (GPs) who had practiced for at
least 2 years since completing their specialist training.
Specialists had to have treated at least 75 patients with hyper-
cholesterolemia with pharmacological therapies in the
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previous 12 months. GPs had to have treated at least 50 such
patients; this requirement was reduced to 25 in Croatia, the
Czech Republic, and Denmark following feedback that this
criterion was higher than the typical caseload of GPs in these
countries. Clinicians were eligible to participate if they had
treated at least five patients with statin intolerance in the pre-
vious 12 months.
The numbers of GPs and specialists varied across coun-
tries. The minimum number of specialists was pre-
determined depending on the available pool of clinicians,
and more GPs were recruited in countries where the minimum
number of specialists was lower. Clinicians were recruited
from different regions in each country.
Statistical Analysis
All data were analyzed separately for each country according
to a pre-specified statistical analysis plan. Analyses used de-
scriptive statistics only since the survey was not designed or
powered tomake statistical comparisons between countries. In
addition, exploratory analyses were planned to report results
separately by clinician type (specialists and GPs).
All analyses were carried out using the statistical software
package SAS (version 9.2 or later) and were independently
verified by a statistician.
Results
Demographics of Study Participants
In total, 2002 clinicians were screened for participation in the
survey; of these, 1003 (50%) met the eligibility criteria and
690 (69% of eligible clinicians) completed the survey. The
planned sample size of 60 per country was met in all countries
except Croatia, where 30 clinicians (15 specialists and 15
GPs) were recruited.
The number of specialists and GPs who completed the
survey in each country is shown in Table 1. All specialists
were cardiologists except in Russia, Saudi Arabia, and the
UAE, where 15% of specialists were endocrinologists.
Signs and Symptoms Associated with Statins
Respondents across all countries except Russia reported that
muscle-related symptoms were the most common symptom
among patients presenting with potential SAS (range across
all countries 17–74%; average of 51%) (Fig. 1). Clinicians in
Russia reported that the most frequently seen sign or symptom
was persistent elevation in transaminases (41% of patients)
compared with 8–32% across the remaining countries.
Across the countries, an average of 15% of patients (range
across all countries 9–24%) were reported to present with
elevated levels of creatine kinase but no muscle symptoms;
an average of 51% of clinicians routinely measured creatine
kinase in all patients newly prescribed statins (range across all
countries 35–67%). An average of 13% of patients (range
across all countries 4–25%) were reported to present with
other symptoms (e.g., gastrointestinal symptoms or alopecia).
Patients were much less commonly reported to present with
CNS effects (range across all countries 2–8%; average of 4%
of patients).
Minimum Criteria Used in Clinical Practice to Establish
SAS in Patients with Muscle-Related Symptoms
Clinicians were asked to identify the minimum criteria that
they use to establish SAS in patients presenting with
muscle-related symptoms (i.e., SAMS). The following op-
tions suggested in the questionnaire were:
& discontinuation or lowering the statin dose to assess the
effect on signs or symptoms, including when followed by
rechallenge;
& modification of the statin regimen through change in the
statin type, dose, or dosing schedule;
& evaluation of creatine kinase levels after discontinuation
or lowering of the statin dose; and
& consideration of other causes for signs or symptoms.
Rechallenge
Rechallenge was defined as identifying whether a patient’s
symptoms or signs improve or resolve when statin treatment
is discontinued but recommence when a statin is restarted. It
Table 1 Number of specialists and GPs who completed the survey
Country Number of specialists
(% of total)
Number of GPs
(% of total)
Austria 20 (33%) 40 (67%)
Belgium 33 (55%) 27 (45%)
Colombia 20 (33%) 40 (67%)
Croatia 15 (50%) 15 (50%)
Czech Republic 20 (33%) 40 (67%)
Denmark 23 (38%) 37 (62%)
Portugal 15 (25%) 45 (75%)
Russia 33 (55%) 27 (45%)
Saudi Arabia 40 (67%) 20 (33%)
Switzerland 28 (47%) 32 (53%)
Turkey 30 (50%) 30 (50%)
United Arab Emirates 33 (55%) 27 (45%)
GP general/family physician
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was reported as a minimum criterion by an average of 71% of
clinicians (range across all countries: 40–90%) (Fig. 2). In
most countries (9 of 12), specialists were more likely to re-
quire this criterion than GPs: on average 75% of specialists
(range across all countries 42–95%) selected this criterion
compared with 67% of GPs (range across all countries 37–
95%). Those who did not report rechallenge with statins
would usually either discontinue the statin or lower the dose
to establish whether symptoms improve or resolve; only a
small number of clinicians (range across all countries 0–
15%) selected none of these options.
Modification
Modification of the statin regimen was commonly reported by
clinicians as a minimum criteria used to establish SAS
in patients presenting with muscle-related symptoms
(i.e., SAMS). An average of 74% clinicians (range across all
countries 32–90%) reported that they would try at least one
alternative statin before considering a patient with muscle-
related symptoms to have SAS; an average of 59% clinicians
(range across all countries 27–80%) would try at least two
alternative statins (Fig. 3). These criteria were selected by
similar proportions of specialists and GPs: 72% of specialists
would try at least one alternative statin and 59% would try at
least two, compared with 76 and 58% of GPs. An average of
30% of clinicians (range across all countries 0–60%) would
try at least one statin at a lower dose, at least one statin at an
intermittent dose, and at least two alternative statins.
Other Criteria
Two other proposed criteria were widely considered as a min-
imum requirement. An average of 86% of clinicians (range
SAS, statin-associated symptoms; UAE, United Arab Emirates
Fig. 1 Patients (%) presenting
with potential SAS who have
muscle-related symptoms
SAS, statin-associated symptoms; UAE, United Arab Emirates
Fig. 2 Clinicians (%) who
rechallenge as a minimum
requirement before considering
muscle-related symptoms to be
SAS
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across all countries 77–100%) would recheck serum creatine
kinase levels after stopping or modifying statin therapy in
patients with previously elevated serum creatine kinase levels
and potential SAS with muscle-related symptoms (i.e.,
SAMS).
Exclusion of other potential causes of symptoms is also
part of recently proposed definitions of statin intolerance;
[12, 16] this was selected as part of the minimum set of criteria
for establishing SAS in patients with muscle-related symp-
toms by 57% of clinicians (range across all countries 15–
87%). Similar proportions of specialists and GPs reported
using each of these criteria.
Minimum Criteria Used in Clinical Practice to Establish
SAS in Patients with Persistent Elevation
of Transaminases
In Russia, persistent elevation of transaminases was reported
to be the most common presenting sign/symptom of potential
SAS. For these patients, a higher proportion of clinicians re-
quired rechallenge, and would try at least two alternative
statins, than for patients with muscle-related symptoms.
Estimates of the Prevalence of SAS
Although this study was not designed as an epidemiological
study, the prevalence of SAS was estimated based on clini-
cians’ responses: clinicians were asked what proportion of
patients newly prescribed statins present with signs or symp-
toms that could be due to intolerance (i.e., SAS), and what
proportion of these patients are later confirmed to be unable to
tolerate statins at a dose below the label recommendation (ac-
cording to the clinicians’ own criteria).
An average of 12% of patients with hypercholesterolemia
who are treated with statins across these 12 countries are re-
ported to have signs and symptoms that may indicate SAS
(range 7–21%); of these, an average of 23% (range across
all countries 12–34%) are unable to tolerate statins at the rec-
ommended therapeutic dose. Therefore, it is estimated that an
average of 2.7% of the total patient population (23% of the
12% of patients presenting with symptoms) are confirmed as
being unable to tolerate statins at the recommended therapeu-
tic dose (range across all countries 1.1–4.8%) (Fig. 4). This
reported percentage was similar for specialists (0.5–5.3%, av-
erage 2.7%) and GPs (0.9–4.5%, average 3.3%).
Of the estimated 2.7% of patients confirmed to have SAS,
an average of 55% was estimated to have muscle-related
symptoms (i.e., SAMS). This ranged from 30% in Russia to
70% in Denmark, and was the most prevalent sign or symp-
tom in all countries except Russia, where persistent elevation
in transaminases was the most common symptom among pa-
tients confirmed as statin intolerant (47% of patients).
Treatment Strategies for Patients with SAS
Clinicians were asked how they treat patients at high cardio-
vascular risk who are unable to tolerate statins at the recom-
mended therapeutic dose. Clinicians across all countries re-
ported that an average of 53% of their high-risk patients with
confirmed SAS continue to receive a lower-dose statin (range
across all countries 43–72%; defined in the questionnaire as
lower than the recommended daily or weekly therapeutic
dose). An average of 65% of these patients would receive
another non-statin lipid-lowering therapy with or without a
concomitant statin (range across all countries 52–83%), and
some patients (average 12%, range across all countries 5–
23%) did not receive any statins or other non-statin lipid-
SAS, statin-associated symptoms, UAE, United Arab Emirates
Fig. 3 Clinicians (%) who try ≥2
alternative statins before
considering muscle-related
symptoms to be SAS
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lowering therapies. Figure 5 summarizes the treatment path-
way inferred from clinicians’ responses across countries for
patients who are unable to tolerate statins at the recommended
therapeutic dose. There was little difference between special-
ists and GPs across countries in the use of lower-dose statins
(on average 53 and 51% of their patients, respectively), their
use of non-statin lipid-lowering therapy (30 and 29% of their
patients, respectively), or the proportion of their patients who
did not receive any statins or other non-statin lipid-lowering
therapies (13 and 12%, respectively).
Clinicians were asked whether they used vitamin D sup-
plementation to ameliorate SAS: 35% of respondents indicat-
ed that they did so, although use varied considerably between
countries (13% in Croatia compared with 80% in the UAE).
Use of Non-Statin Lipid-Lowering Therapies
Clinicians were asked which non-statin therapies they
used most frequently for patients with confirmed SAS.
Ezetimibe was the most common first-choice non-statin
therapy used without a concomitant statin in 10 of 12
countries (first choice of 55% of clinicians across coun-
tries), but the choice of therapy differed between coun-
tries and between GPs and specialists (Table 2). Fibrates
were the first choice of the majority of both specialists
and GPs in Saudi Arabia and the UAE (listed therapies
included fenofibrate, bezafibrate, ciprofibrate, and gem-
fibrozil); fibrates were the first choice of GPs in the
Czech Republic and Turkey.
Proportions were estimated using country-level data.
UAE, United Arab Emirates
Fig. 4 Estimated proportion of
patients confirmed to have statin
intolerance
Data summarized across 12 countries; ranges shown across countries. Values may not sum to 100% due to rounding.
Fig. 5 Treatment strategies for patients who cannot tolerate statins at the recommended therapeutic dose
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Clinicians in all countries reported similar choices of non-
statin therapy for use in combination with lower-dose statin
regimens (a daily or weekly dose lower than the recommend-
ed therapeutic dose).
Alignment of Responses with Clinical Guidelines
The results of this survey align well with recent clinical prac-
tice guidelines for the management of patients presenting with
potential SAMS (European Atherosclerosis Society
Consensus Panel [10] and US National Lipid Association
[11]). On average, the clinicians surveyed stated that they
undertake the recommended measures to establish whether a
patient’s symptoms are associated with statin use. The major-
ity of clinicians stated that they tried statin washout followed
by rechallenge, tried alternative statins, and would wish to
exclude alternative causes of symptoms. Regarding the man-
agement of patients identified as statin intolerant, the clini-
cians stated that they use lower-dose statins where tolerated
and also use non-statin lipid-lowering therapies (with
ezetimibe as first choice) in order for patients to achieve their
low-density lipoprotein cholesterol goal; both of these strate-
gies are recommended in the guidelines.
For both identification and management of patients, how-
ever, there were differences between countries in whether the
majority of clinicians’ practice aligned with these guidelines;
this is discussed below.
Discussion
This study extends our previous work [17] to an additional 12
countries. The aim was to elicit responses from clinicians who
were experienced in managing patients with SAS, and to un-
derstand their routine clinical practice. As in the previous
work, clinicians in most countries surveyed stated that they
required relatively stringent criteria to be fulfilled to establish
SAS (typically SAMS or other signs/symptoms of intoler-
ance), including rechallenging after discontinuation to identify
the association of symptoms, use of alternative statins, and
exclusion of other potential causes of signs/symptoms.
The estimated prevalence of confirmed SAS was less than
3% in 8 of the 12 countries, which is lower than the prevalence
reported in observational studies of about 10% [5–8]. The
estimate from our study is based on clinicians’ own defini-
tions, and may include patients who continue to receive a
lower dose of statin if the clinician considers them to have
SAS. This suggests that clinicians are usually stringent in
excluding other possible causes when evaluating patients with
signs or symptoms of potential SAS. Variation between coun-
tries may reflect the actual prevalence of signs and symptoms
(potentially influenced by the dosage and type of statin pre-
scribed), and the attitude of patients towards side-effect
reporting.
Clinicians’ responses suggest that approximately half of
high-risk patients continue to receive a lower-dose statin (with
unknown adherence), and the majority are also prescribed an
alternative lipid-lowering therapy: a pattern consistent with
the previous countries surveyed. However, a proportion of
patients (estimated to be over 10% in 7 of the 12 countries
surveyed) do not receive any treatment.
The objective of this work was not to make comparisons
among countries, but to identify practice patterns on a country
level. However, some differences between countries in both
the identification and management of patients with SAS are
clear:
& As in the previous survey, muscle symptoms were most
commonly reported as a presenting sign or symptom of
statin side effects, particularly in Western European coun-
tries. Elsewhere, other signs/symptoms were considered
more frequent; persistent elevation of transaminases was
reported to be the most common presenting sign or symp-
tom in Russia. This may reflect the frequency of monitor-
ing: in Russia, over 90% of clinicians reported testing for
transaminase elevation in all patients newly prescribed
statins, compared with an average of 79% across all coun-
tries (range 60–92%). Other considerations may be clini-
cal (statin dosing, genetic factors, comorbidities such as
viral hepatitis and alcohol abuse) or cultural factors.
& The stringency of the criteria that had to be met for a
patient to be considered to have SAS (typically SAMS
Table 2 First choices of non-statin monotherapy for patients with con-
firmed SAS
Country Most common first-choice therapy (% of clinicians
selecting as first choice)
Specialists GPs
Austria Ezetimibe (85%) Ezetimibe (64%)
Belgium Ezetimibe (85%) Ezetimibe (63%)
Colombia Ezetimibe (42%) Ezetimibe (47%)
Croatia Ezetimibe (62%) Fibratesa (43%)
Czech Republic Ezetimibe (80%) Fibratesa (84%)
Denmark Ezetimibe (91%) Ezetimibe (91%)
Portugal Ezetimibe (79%) Ezetimibe (68%)
Russia Ezetimibe (43%) Ezetimibe (39%)
Saudi Arabia Fibratesa (66%) Fibratesa (53%)
Switzerland Ezetimibe (89%) Ezetimibe (81%)
Turkey Ezetimibe (66%) Fibratesa (66%)
UAE Fibratesa (67%) Fibratesa (56%)
a Clinicians selected from a list of therapies including fenofibrate,
bezafibrate, ciprofibrate, and gemfibrozil; there were differences in the
frequency of selection of individual fibrates between countries
GP general/family physician, UAE United Arab Emirates
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or other signs/symptoms of intolerance) was similar across
most countries; however, notably fewer clinicians in the
Russia, Turkey, and the UAE reported requiring rechal-
lenge and fewer reported trying multiple statins.
& Unlike in the previous survey, where ezetimibe was the
most commonly selected therapy for use in patients with
SAS in all countries, there were some regional differences
in the choice of therapy; for example, fibrates were the
first-choice alternative to statins for clinicians in the two
Middle Eastern countries. This choice of therapy may be
influenced by the local prevalence of mixed dyslipidemia,
country- and region-specific clinical evidence, or local
reimbursement, marketing, and experience of particular
agents. Differences between specialists and GPs may re-
flect familiarity or local reimbursement restrictions that
require specialist prescribing.
Limitations
The anonymous nature of the data collection and analyses
aims to ensure that the results of this survey can provide in-
sight into clinical practice for patients with SAS in each of the
countries surveyed. However, the restriction of participants to
those who managed a certain number of patients with hyper-
cholesterolemia and with statin intolerance is a limitation of
this work, and may mean that the responses cannot be gener-
alized to all clinicians in their country. There is also a bias
towards clinicians willing to participate in such research.
The survey also relies on clinicians’ responses and hence their
recall, rather than using patient-level data to identify the deci-
sions they actually make in practice. Comparison with the
results of an alternative methodology (e.g., review of medical
records), would be informative to understand the extent of
correlation between clinician-reported practice and patient-
level records. We recognize that patient and physician per-
spectives concerning statin intolerance vary. The use of a stan-
dardized validated tool has been proposed to improve the ac-
curacy of identification of statin versus non-statin-associated
muscle symptoms [18].
Conclusions
In line with the findings of the previous work, this survey
provides evidence that clinicians have a somewhat uniform
way of defining SAS. In general, stringent criteria are used
to establish whether the relationship between statins and signs
or symptoms is causal and most clinicians strive to continue
statin treatment for their patients at high cardiovascular risk
where possible. The expanded geographic scope provides a
broader understanding of similarities and differences across
countries: differences between countries were identified in
the most frequently presented sign or symptom of SAS, and
in the choice of non-statin lipid-lowering therapies.
Recently there has been increased interest in the manage-
ment of patients with SAS, exemplified by numerous guide-
lines at a national and international level, [9–12, 15, 16]
and the recent publication of a clinical index for identification
of SAMS [18]. This, coupled with increasing treatment op-
tions and evidence of the effectiveness of alternative lipid-
lowering therapies, suggests that control of hypercholesterol-
emia in such patients can be improved. Only a small minority
of all patients prescribed statins are not able to tolerate any
statin dose; however, given the established beneficial effect of
statins [4] and potential harm of down-titrating or
discontinuing statin therapy [14], it is essential that clinicians
do utilize stringent criteria, such as rechallenge, and try treat-
ment strategies such as lower- or intermittent-dosing, in order
to ensure statin use in the largest possible proportion of pa-
tients at high cardiovascular risk.
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